Search results for "Luce."

showing 10 items of 139 documents

Evaluation of treatment response to enzyme replacement therapy with Velaglucerase alfa in patients with Gaucher disease using whole-body magnetic res…

2015

Abstract Objective This was a retrospective data analysis to evaluate the treatment response to enzyme replacement therapy (ERT) with Velaglucerase alfa using whole-body magnetic resonance imaging (MRI). Materials and methods A baseline and follow-up MRI were performed on 18 Gaucher Type 1 patients at an interval of 11.6 months. The MRI score systems determined the Bone-Marrow-Burden (BMB) score, the Dusseldorf-Gaucher score (DGS), and the Vertebra-Disc-Ratio (VDR). The Severity Score Index Type 1 (GD-DS3) was also assessed. Results The baseline MRI medians were: BMB, 7.00; DGS, 3.00; and VDR: 1.70; while, the follow-up MRI medians were: BMB, 7.00; DGS, 3.00; and VDR: 1.73. The baseline GD-…

0301 basic medicineAdultMalemedicine.medical_specialtyWhole body imagingSeverity of Illness Index03 medical and health sciences0302 clinical medicineBone MarrowStatistical significanceSeverity of illnessmedicineHumansEnzyme Replacement TherapyWhole Body ImagingStage (cooking)Molecular BiologyAgedRetrospective StudiesGaucher Diseasemedicine.diagnostic_testbusiness.industryVelaglucerase alfaPlatelet CountMagnetic resonance imagingRetrospective cohort studyCell BiologyHematologyEnzyme replacement therapyMiddle AgedMagnetic Resonance ImagingRecombinant ProteinsSurgery030104 developmental biologyTreatment OutcomeMolecular MedicineGlucosylceramidaseFemaleRadiologybusiness030215 immunologymedicine.drugFollow-Up StudiesBlood cells, moleculesdiseases
researchProduct

Automatic detection and measurement of nuchal translucency.

2017

In this paper we propose a new methodology to support the physician both to identify automatically the nuchal region and to obtain a correct thickness measurement of the nuchal translucency. The thickness of the nuchal translucency is one of the main markers for screening of chromosomal defects such as trisomy 13, 18 and 21. Its measurement is performed during ultrasound scanning in the first trimester of pregnancy. The proposed methodology is mainly based on wavelet and multi resolution analysis. The performance of our method was analysed on 382 random frames, representing mid-sagittal sections, uniformly extracted from real clinical ultrasound videos of 12 patients. According to the groun…

0301 basic medicinemedicine.medical_specialtyWavelet AnalysisFirst trimester of pregnancyHealth InformaticsSensitivity and SpecificityWavelet analysi030218 nuclear medicine & medical imagingPattern Recognition AutomatedMachine Learning03 medical and health sciencesPrenatal ultrasound0302 clinical medicineNuchal regionNuchal translucencyUltrasound fetal examinationMedian sagittal sectionNuchal Translucency MeasurementImage Interpretation Computer-AssistedMedicineHumansPixelbusiness.industryMulti resolution analysisUltrasoundReproducibility of ResultsPattern recognitionComputer Science Applications1707 Computer Vision and Pattern RecognitionComputer Science ApplicationsSurgeryClinical ultrasound030104 developmental biologyNuchal translucencyArtificial intelligenceDown SyndromebusinessNuchal Translucency MeasurementAlgorithmsComputers in biology and medicine
researchProduct

Patients' and physicians' preferences for type 2 diabetes mellitus treatments in Spain and Portugal: a discrete choice experiment.

2015

Objective: To assess Spanish and Portuguese patients' and physicians' preferences regarding type 2 diabetes mellitus (T2DM) treatments and the monthly willingness to pay (WTP) to gain benefits or avoid side effects. Methods: An observational, multicenter, exploratory study focused on routine clinical practice in Spain and Portugal. Physicians were recruited from multiple hospitals and outpatient clinics, while patients were recruited from eleven centers operating in the public health care system in different autonomous communities in Spain and Portugal. Preferences were measured via a discrete choice experiment by rating multiple T2DM medication attributes. Data were analyzed using the cond…

:Geographicals::Geographic Locations::Europe::Portugal [Medical Subject Headings]cardiovascular riskHbA1cendocrine system diseases:Analytical Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Physical Examination::Body Constitution::Body Weights and Measures::Body Mass Index [Medical Subject Headings]:Diseases::Nutritional and Metabolic Diseases::Metabolic Diseases::Glucose Metabolism Disorders::Hypoglycemia [Medical Subject Headings]:Disciplines and Occupations::Health Occupations::Medicine::Public Health [Medical Subject Headings]:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Risk::Risk Factors [Medical Subject Headings]:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]:Named Groups::Persons::Occupational Groups::Health Personnel::Physicians [Medical Subject Headings]HbA(1c)HbA:Diseases::Pathological Conditions Signs and Symptoms::Signs and Symptoms::Body Weight::Body Weight Changes::Weight Loss [Medical Subject Headings]:Diseases::Cardiovascular Diseases [Medical Subject Headings]preferences:Geographicals::Geographic Locations::Europe::Spain [Medical Subject Headings]diabetesnutritional and metabolic diseasesPeso corporalweightPérdida de peso:Health Care::Health Care Facilities Manpower and Services::Health Facilities::Ambulatory Care Facilities [Medical Subject Headings]Diabetes mellitus tipo 2:Diseases::Pathological Conditions Signs and Symptoms::Signs and Symptoms::Signs and Symptoms Digestive::Nausea [Medical Subject Headings]hypoglycemia:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Models Statistical::Logistic Models [Medical Subject Headings]:Diseases::Pathological Conditions Signs and Symptoms::Signs and Symptoms::Body Weight [Medical Subject Headings]:Diseases::Nutritional and Metabolic Diseases::Metabolic Diseases::Glucose Metabolism Disorders::Diabetes Mellitus::Diabetes Mellitus Type 2 [Medical Subject Headings]:Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Physiological Effects of Drugs::Hypoglycemic Agents [Medical Subject Headings]Enfermedades cardiovascularesHipoglucemiawillingness to pay:Check Tags [Medical Subject Headings]discrete choice model
researchProduct

First-trimester screening for trisomy-21 using a simplified method to assess the presence or absence of the fetal nasal bone.

2005

Objective To determine the benefit of including nasal bone assessment in addition to standard first-trimester markers (nuchal translucency, free beta human chorionic gonadotropin and pregnancy-associated plasma protein A) as a screening test for Down syndrome, using a strict criterion for classification of nasal bone absence. Study design Nasal bone assessment was conducted in 2411 patients with crown-rump length between 45 and 84 mm, including 15 patients with Down syndrome. A patient was considered to have an absent nasal bone only if there was no evidence of present nasal bone. Unlike other studies, nasal bone was classified as present when there was evidence of a thin echogenic line und…

AdultDown syndromemedicine.medical_specialtyPregnancy-associated plasma protein AUrologyAneuploidyPrenatal diagnosisEmbryonic StructuresSensitivity and SpecificityCrown-Rump LengthUltrasonography PrenatalPredictive Value of TestsPregnancyReference ValuesRisk FactorsmedicineConfidence IntervalsHumansMass ScreeningNasal BoneProbabilityObstetricsbusiness.industryObstetrics and GynecologyEchogenicityPrenatal Caremedicine.diseaseNasal boneConfidence intervalPregnancy Trimester FirstCase-Control StudiesLinear ModelsFemaleDown SyndromeTrisomybusinessNuchal Translucency MeasurementAmerican journal of obstetrics and gynecology
researchProduct

Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial

2022

AbstractThe STEP 5 trial assessed the efficacy and safety of once-weekly subcutaneous semaglutide 2.4 mg versus placebo (both plus behavioral intervention) for long-term treatment of adults with obesity, or overweight with at least one weight-related comorbidity, without diabetes. The co-primary endpoints were the percentage change in body weight and achievement of weight loss of ≥5% at week 104. Efficacy was assessed among all randomized participants regardless of treatment discontinuation or rescue intervention. From 5 October 2018 to 1 February 2019, 304 participants were randomly assigned to semaglutide 2.4 mg (n = 152) or placebo (n = 152), 92.8% of whom completed the trial (attended t…

AdultMaleGlucagon-Like PeptideHypoglycemic AgentObesidadInvestigación médicaGeneral MedicineMiddle AgedOverweightWeight LoGeneral Biochemistry Genetics and Molecular BiologyTratamiento médicoTreatment OutcomeDouble-Blind MethodDiabetes Mellitus Type 2GlucemiaControl glucémicoFemaleObesitySettore MED/49 - Scienze Tecniche Dietetiche ApplicateHuman
researchProduct

Baseline characteristics and outcome in Romanian patients with Gaucher disease type 1.

2009

Abstract Background/aim To present clinical and genetic characteristics of all Romanian patients with Gaucher disease type 1, in whom specific diagnosis has been confirmed by enzymatic and molecular methods and to analyze their outcome with and without enzymatic replacement therapy (ERT). Patients, methods There are fifty patients (F/M — 1.63/1) with Gaucher disease type 1. Clinical status, haemoglobin, thrombocytes, hepatic/splenic volume, bone mineral density and severity score were assessed at baseline and every six months thereafter. Thirty-nine patients (78%) received imiglucerase (44.4 ± 13.6 U/kg/2 weeks) for 3.1 +/− 1.4 years. Results Based on general prevalence data, our group repr…

AdultMalemedicine.medical_specialtyEvery Six MonthsBone diseaseImigluceraseAdolescentGenotypeDiseaseGastroenterologyYoung AdultInternal medicineGenotypeInternal MedicinemedicineHumansPlateletAge of OnsetChildAllelesBone mineralGaucher Diseasebusiness.industryRomaniaInfantAnemiaMiddle Agedmedicine.diseasePrognosisThrombocytopeniaSurgeryHexosaminidasesChild PreschoolMutationSplenomegalyGlucosylceramidaseFemalebusinessVisceromegalymedicine.drugEuropean journal of internal medicine
researchProduct

Development and application to clinical practice of a validated HPLC method for the analysis of β-glucocerebrosidase in Gaucher disease.

2014

The main objective of our study is to develop a simple, fast and reliable method for measuring ß-glucocerebrosidase activity in Gaucher patients leukocytes in clinical practice. This measurement may be a useful marker to drive dose selection and early clinical decision making of enzyme replacement therapy. We measure the enzyme activity by high-performance liquid chromatography with ultraviolet detection and 4-nitrophenyl-ß-d-glucopyranoside as substrate. A cohort of eight Gaucher patients treated with enzyme replacement therapy and ten healthy controls were tested; median enzyme activity values was 20.57mU/ml (interquartile range 19.92-21.53mU/ml) in patients and mean was 24.73mU/ml (24.12…

AdultMalemedicine.medical_specialtyImigluceraseAdolescentUltraviolet RaysClinical BiochemistryUrologyPharmaceutical ScienceAnalytical ChemistryInterquartile rangeDrug DiscoverymedicineLeukocytesHumansDosingProspective StudiesProspective cohort studyChildSpectroscopyEnzyme activity Gaucher disease HPLC Imiglucerase ß-GlucocerebrosidaseChromatography High Pressure LiquidGaucher DiseasebiologyChemistryEnzyme replacement therapyMiddle AgedEnzyme assayGlucosylceramidaseBiochemistrybiology.proteinGlucosylceramidaseFemaleGlucocerebrosidasemedicine.drugJournal of pharmaceutical and biomedical analysis
researchProduct

Evaluation of Bone Marrow Infiltration in Non-Neuropathic Gaucher Disease Patients with Use of Whole-Body MRI--A Retrospective Data Analysis.

2015

Purpose: To evaluate whole-body magnetic resonance imaging (WB-MRI) for the assessment of bone marrow infiltration in patients with confirmed Gaucher disease type 1 under long-term enzyme replacement therapy (ERT). Materials and Methods: This retrospective data analysis included 38 patients in two subgroups. Group A: 10 females, 9 males, 15 – 29 years, mean age 22 years and Group B: 11 females, 8 males, 29 – 77 years, mean age 49 years, all treated with alglucerase or imiglucerase for at least 12.5 years. Whole-body MRI was carried out in all patients using a standard MRI protocol. Two radiologists assessed all MR images retrospectively with the use of three different MRI score systems: The…

AdultMalemedicine.medical_specialtyImigluceraseAdolescentYoung AdultAlgluceraseBone MarrowmedicineHumansRadiology Nuclear Medicine and imagingWhole Body ImagingYoung adultAgedRetrospective StudiesGaucher Diseasemedicine.diagnostic_testbusiness.industryMagnetic resonance imagingRetrospective cohort studyEnzyme replacement therapyMiddle AgedMagnetic Resonance ImagingSurgeryVertebramedicine.anatomical_structureBody BurdenFemaleRadiologyBone marrowbusinessmedicine.drugRoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin
researchProduct

Expression of caveolin-1 in tooth germ, ameloblastoma and ameloblastic carcinoma

2020

Background The caveolin-1 protein (structural component of membrane caveolae) plays important roles in several biological functions, such as endocytosis, cell adhesion, and cell signaling. However, this protein has been associated with mechanisms of tumorigenesis in several neoplasms. The expression patterns and roles of caveolin-1 in the oral epithelium and in embryonic and odontogenic tumor tissues are still unclear. Material and Methods The expression of caveolin-1 was evaluated in samples of the normal gingival epithelium (n=7), human tooth germ (TG) (n=12), ameloblastoma (AM) (n=83), and ameloblastic carcinoma (AC) (n=9) by immunohistochemistry. Additionally, AM samples were analyzed b…

AdultPathologymedicine.medical_specialtyReal Time Polymerase Chain Reactionrecurrencegovernment.form_of_governmentCaveolin 1Odontogenic TumorsBiologymedicine.disease_causeAmeloblastic CarcinomaMalignant transformationAmeloblastomaWestern blotCaveolin-1medicineHumansCaveolina 1resectionAmeloblastomaGeneral DentistrycurettageUNESCO:CIENCIAS MÉDICASdesmoplastic ameloblastomaOral Medicine and Pathologymedicine.diagnostic_testResearchmixed radiopaque ? radiolucentCarcinomaOdontogenic tumorTooth Germmedicine.diseaseImmunohistochemistryAmeloblastic carcinomaOtorhinolaryngologyCaveolin 1governmentImmunohistochemistrySurgeryCarcinogenesisenucleationMedicina Oral, Patología Oral y Cirugía Bucal
researchProduct

Prospective sonographic detection of spina bifida at 11–14 weeks and systematic literature review

2015

Objective: To conduct a literature review to assess the effectiveness of first trimester ultrasonographic markers of spina bifida (SB) integrating data with our prospective experience. Methods: The analysis of the SB cases that we prospectively detected in the first trimester, between January 2012 and February 2014, and a systematic review of all the papers evaluating the effectiveness of SB ultrasonographic markers at 11–14 weeks, namely brain stem diameter (BS), fourth ventricle/intracranial translucency (IT), cisterna magna (CM), brain stem/occipital bone distance (BSOB), the ratio between BS and BSOB. Some studies assess only the effectiveness of IT, others include more parameters, and …

AdultPediatricsmedicine.medical_specialtyBrain stem cisterna magna first trimester screening fossa intracranial translucency neural tube defect posterior ultrasoundLow risk populationCisterna magnaFourth ventricleUltrasonography PrenatalPregnancyCisterna MagnamedicineHumansProspective StudiesProspective cohort studySpinal DysraphismFourth VentriclePregnancyNeural tube defectbusiness.industrySpina bifidaObstetrics and Gynecologymedicine.diseasePregnancy Trimester FirstSystematic reviewOccipital BonePediatrics Perinatology and Child HealthFemaleNuclear medicinebusinessBrain StemThe Journal of Maternal-Fetal & Neonatal Medicine
researchProduct